Calliditas Therapeutics Says FDA Granted Priority Review of Tarpeyo for Treatment of Immunoglobulin A Nephropathy
Calliditas Therapeutics Says FDA Granted Priority Review of Tarpeyo for Treatment of Immunoglobulin A Nephropathy
Calliditas Therapeutics表示,美國食品藥品管理局已批准對用於治療A型免疫球蛋白腎病的Tarpeyo進行優先審查
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊